Short answer
ANAPTYSBIO, INC (ANAB) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q4 and full-year 2025 financial results announced March 3, 2026.
ANAPTYSBIO, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results announced March 3, 2026
- Detailed figures in Exhibit 99.1 press release: key metrics not disclosed in this filing item
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure: AnaptysBio releasing investor presentation (Exhibit 99.2): signals potential pipeline, clinical, or strategic update material to valuation
- Full content in Exhibit 99.2; investors should review directly for pipeline timelines, data readouts, or partnering details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANAPTYSBIO, INC 8-K filings
Get the next ANAB 8-K as it lands
Follow ANAB for push alerts, or ask the research agent what this filing means.